Safety of long-term PPI therapy.
暂无分享,去创建一个
[1] D. Coppola,et al. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. , 1998, American journal of clinical pathology.
[2] J. Hoenderop,et al. Systematic review: hypomagnesaemia induced by proton pump inhibition , 2012, Alimentary pharmacology & therapeutics.
[3] S. Bandinelli,et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. , 2013, JAMA internal medicine.
[4] J. Rood,et al. Influence of Gastric Acid on Susceptibility to Infection with Ingested Bacterial Pathogens , 2007, Infection and Immunity.
[5] J. Powell,et al. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis , 2007, Gut.
[6] C. Reimer,et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. , 2009, Gastroenterology.
[7] Vivek R. Sharma,et al. Effect of Omeprazole on Oral Iron Replacement in Patients with Iron Deficiency Anemia , 2004, Southern medical journal.
[8] G. Leontiadis,et al. Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies , 2011, The American Journal of Gastroenterology.
[9] J. Lewis,et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. , 2007, Gastroenterology.
[10] E. Kuipers,et al. Proton Pump Inhibitors and the Risk of Colorectal Cancer , 2008, The American Journal of Gastroenterology.
[11] S. Meuwissen,et al. Effect of short‐ and long‐term treatment with omeprazole on the absorption and serum levels of cobalamin , 1996, Alimentary pharmacology & therapeutics.
[12] L. Lundell,et al. Changes of gastric mucosal architecture during long‐term omeprazole therapy: results of a randomized clinical trial , 2006, Alimentary pharmacology & therapeutics.
[13] A. Sandvik,et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. , 1996, Gut.
[14] Gian Franco Gensini,et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report , 2012, Gut.
[15] D. Adler,et al. Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis , 2012, The American Journal of Gastroenterology.
[16] I. Modlin,et al. A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.
[17] Nelis,et al. Atrophic gastritis during long‐term omeprazole therapy affects serum vitamin B12 levels , 1999, Alimentary pharmacology & therapeutics.
[18] A. Blum,et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. , 1994, Gut.
[19] R. Regal,et al. Acid Suppressive Therapy Use on an Inpatient Internal Medicine Service , 2006, The Annals of pharmacotherapy.
[20] E. Kuipers,et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. , 1996, The New England journal of medicine.
[21] T. Cundy,et al. Severe hypomagnesaemia in long‐term users of proton‐pump inhibitors , 2008, Clinical endocrinology.
[22] R. Janssen,et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases , 2007, Epidemiology and Infection.
[23] R. Slack,et al. Diabetes mellitus, anti-secretory drugs and other risk factors for campylobacter gastro-enteritis in adults: a case-control study , 1997, Epidemiology and Infection.
[24] J. Hallas,et al. Use of anti‐secretory medication: a population‐based cohort study , 2004, Alimentary pharmacology & therapeutics.
[25] E. Norkus,et al. Do acid-lowering agents affect vitamin B12 status in older adults? , 2008, Journal of the American Medical Directors Association.
[26] H. Dupont,et al. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection , 2011, Alimentary pharmacology & therapeutics.
[27] M. Loeb,et al. Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia , 2010, Alimentary pharmacology & therapeutics.
[28] R. Fiocca,et al. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. , 1992, Digestion.
[29] R. Cavallazzi,et al. Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis , 2012, The American Journal of Gastroenterology.
[30] Gideon Koren,et al. The Safety of Proton Pump Inhibitors (PPIs) in Pregnancy: A Meta-Analysis , 2009, The American Journal of Gastroenterology.
[31] T. Strandberg,et al. Use of proton pump inhibitors and mortality among institutionalized older people. , 2010, Archives of internal medicine.
[32] P. Siersema,et al. Proton pump inhibitor therapy predisposes to community‐acquired Streptococcus pneumoniae pneumonia , 2012, Alimentary pharmacology & therapeutics.
[33] B. Batuwitage,et al. Inappropriate prescribing of proton pump inhibitors in primary care , 2007, Postgraduate Medical Journal.
[34] N. Havu,et al. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. , 1991, Gastroenterology.
[35] Walsh,et al. Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors , 2000, Alimentary pharmacology & therapeutics.
[36] Jonkers,et al. Serum gastrin and chromogranin A during medium‐ and long‐term acid suppressive therapy: a case‐control study , 1999, Alimentary pharmacology & therapeutics.
[37] R. Shangraw,et al. Nutritional and pharmaceutical aspects of calcium supplementation. , 1987, American pharmacy.
[38] M. Kuczmarski,et al. Vitamin B12 Deficiency is Linked with Long-Term Use of Proton Pump Inhibitors in Institutionalized Older Adults: Could a Cyanocobalamin Nasal Spray be Beneficial? , 2010, Journal of nutrition for the elderly.
[39] R. Slack,et al. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study , 1996, BMJ.
[40] J. Dent,et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. , 2000, Gastroenterology.
[41] Y. V. van Duynhoven,et al. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections , 2005, Epidemiology and Infection.
[42] J. R. Graham. Gastric polyposis: onset during long‐term therapy with omeprazole , 1992, The Medical journal of Australia.
[43] E. Kuipers,et al. A case series of proton pump inhibitor-induced hypomagnesemia. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[44] R. Pounder,et al. Drug-induced changes of plasma gastrin concentration. , 1990, Gastroenterology clinics of North America.
[45] Y. V. van Duynhoven,et al. Risk factors for indigenous Campylobacter jejuni and Campylobacter coli infections in The Netherlands: a case-control study , 2010, Epidemiology and Infection.
[46] H. Jick,et al. Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors , 2008, Pharmacotherapy.
[47] Yu-Xiao Yang,et al. Long-term proton pump inhibitor therapy and risk of hip fracture. , 2006, JAMA.
[48] J. Manson,et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. , 2010, Archives of internal medicine.
[49] Miriam C J M Sturkenboom,et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. , 2004, JAMA.
[50] A. Sandvik,et al. The enterochromaffin-like (ECL) cell. Physiological and pathophysiological role. , 1993, Acta oncologica.
[51] M. Howell,et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. , 2010, Archives of internal medicine.
[52] K. Abe,et al. Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans , 1993, Calcified Tissue International.
[53] H. Boezen,et al. Increased risk of fundic gland polyps during long‐term proton pump inhibitor therapy , 2006, Alimentary pharmacology & therapeutics.
[54] E. Norkus,et al. Does long-term PPI use result in vitamin B12 deficiency in elderly individuals? , 2008, Nature Clinical Practice Gastroenterology &Hepatology.
[55] A. Borobia,et al. Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Terciary Spanish Hospital , 2010 .
[56] J. Olsen,et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study , 2009, British Journal of Cancer.
[57] J. Mant,et al. Mortality study of 18 000 patients treated with omeprazole , 2003, Gut.
[58] J. Hallas,et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. , 2007, Archives of internal medicine.
[59] A. Rydning,et al. On‐demand requirements of patients with endoscopy‐negative gastro‐oesophageal reflux disease: H2‐blocker vs. proton pump inhibitor , 2009, Alimentary pharmacology & therapeutics.
[60] T. Stadtman,et al. Vitamin B12 , 1971, Science.
[61] S. Jamal,et al. The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: A Population-Based From the Canadian Multicentre Osteoporosis Study (CaMos) , 2012, The American Journal of Gastroenterology.
[62] A. Murray,et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. , 2005, The American journal of medicine.
[63] K. McColl,et al. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. , 1999, Gastroenterology.
[64] N. Sasaki,et al. Helicobacter pylori infection and the development of gastric cancer. , 2001, The New England journal of medicine.
[65] H. Sørensen,et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. , 2007, Gastroenterology.
[66] Sang Min Park,et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis , 2011, Canadian Medical Association Journal.
[67] D. Corley,et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. , 2010, Gastroenterology.
[68] S. Hennessy,et al. Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia , 2008, Annals of Internal Medicine.
[69] P. Vestergaard,et al. Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture , 2006, Calcified Tissue International.
[70] John K Marshall,et al. Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression , 2007, The American Journal of Gastroenterology.
[71] E. Kuipers,et al. Proton pump inhibitors and gastric neoplasia , 2006, Gut.
[72] F. Sundler,et al. Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach. , 1992, Digestion.
[73] P. Khazanie,et al. Omeprazole Therapy Causes Malabsorption of Cyanocobalamin (Vitamin B12) , 1994, Annals of Internal Medicine.
[74] S. Watson,et al. The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin , 1989, International journal of cancer.
[75] D. Reith,et al. Continuation of Proton Pump Inhibitors from Hospital to Community , 2006, Pharmacy World and Science.
[76] E. Björnsson,et al. Dyspeptic Symptom Development After Discontinuation of a Proton Pump Inhibitor: A Double-Blind Placebo-Controlled Trial , 2010, The American Journal of Gastroenterology.
[77] S. le Cessie,et al. Long‐term use of proton pump inhibitors and vitamin B12 status in elderly individuals , 2008, Alimentary pharmacology & therapeutics.
[78] T. Cundy,et al. Proton pump inhibitors and severe hypomagnesaemia , 2011, Current opinion in gastroenterology.